Seasonal influenza vaccine manufacturer Sanofi is attempting to leverage a failed confirmatory trial for Seqirus’ Fluad to its competitive advantage, requesting the US Food and Drug Administration revise Fluad labeling to reflect limitations of the vaccine’s existing efficacy evidence.
In a citizen petition submitted to the FDA on 2 March, Sanofi requests that labeling for Fluad and Fluad...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?